In vitro diagnostics company Accelerate Diagnostics (NASDAQ: AXDX) shared the results of a multicenter study of its Accelerate PhenoTest BC Kit at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) earlier this month.
The product is intended to provide rapid results for patients suspected of having bacteremia or fungemia -- both are potentially life-threatening conditions -- to improve health outcomes.
The PhenoTest BC Kit demonstrated its effectiveness in significantly reducing the time to optimal therapy and to the first antibiotic intervention for treating bloodstream infections.
For further details see:
This In Vitro Diagnostics Company Is Poised to Capture Its Share of a Growing market